Equities analysts expect Repligen Co. (NASDAQ:RGEN) to post earnings per share (EPS) of $0.12 for the current quarter, Zacks reports. Five analysts have made estimates for Repligen’s earnings. The lowest EPS estimate is $0.11 and the highest is $0.13. Repligen posted earnings per share of $0.08 in the same quarter last year, which would indicate a positive year over year growth rate of 50%. The firm is scheduled to announce its next earnings report on Wednesday, February 28th.

On average, analysts expect that Repligen will report full-year earnings of $0.61 per share for the current year, with EPS estimates ranging from $0.57 to $0.63. For the next fiscal year, analysts forecast that the company will report earnings of $0.71 per share, with EPS estimates ranging from $0.68 to $0.75. Zacks’ earnings per share averages are an average based on a survey of research analysts that follow Repligen.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Thursday, November 9th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.04. The company had revenue of $36.58 million for the quarter, compared to analysts’ expectations of $35.69 million. Repligen had a net margin of 16.93% and a return on equity of 7.57%. Repligen’s revenue was up 48.2% compared to the same quarter last year. During the same period in the previous year, the company posted $0.08 EPS.

RGEN has been the topic of several recent research reports. Zacks Investment Research raised shares of Repligen from a “hold” rating to a “buy” rating and set a $43.00 price objective on the stock in a research note on Thursday, October 5th. Citigroup initiated coverage on shares of Repligen in a research note on Friday. They issued a “buy” rating and a $45.00 price objective on the stock. TheStreet raised shares of Repligen from a “c+” rating to a “b-” rating in a research note on Friday, August 11th. J P Morgan Chase & Co initiated coverage on shares of Repligen in a research note on Tuesday. They issued an “overweight” rating and a $42.00 price objective on the stock. Finally, Stephens reissued an “overweight” rating and issued a $50.00 price objective on shares of Repligen in a research note on Tuesday, September 26th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $44.38.

Several hedge funds and other institutional investors have recently modified their holdings of RGEN. JPMorgan Chase & Co. boosted its position in shares of Repligen by 31.9% during the 1st quarter. JPMorgan Chase & Co. now owns 3,755 shares of the biotechnology company’s stock worth $133,000 after purchasing an additional 908 shares in the last quarter. Teachers Advisors LLC boosted its position in shares of Repligen by 2.4% during the 1st quarter. Teachers Advisors LLC now owns 58,081 shares of the biotechnology company’s stock worth $2,044,000 after purchasing an additional 1,386 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Repligen by 7.0% in the 1st quarter. Vanguard Group Inc. now owns 1,809,202 shares of the biotechnology company’s stock worth $63,683,000 after buying an additional 118,585 shares in the last quarter. Bank of America Corp DE boosted its position in shares of Repligen by 55.2% in the 1st quarter. Bank of America Corp DE now owns 93,003 shares of the biotechnology company’s stock worth $3,274,000 after buying an additional 33,084 shares in the last quarter. Finally, Public Employees Retirement System of Ohio boosted its position in shares of Repligen by 16.1% in the 1st quarter. Public Employees Retirement System of Ohio now owns 10,127 shares of the biotechnology company’s stock worth $356,000 after buying an additional 1,401 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Shares of Repligen (NASDAQ RGEN) traded up $0.98 on Monday, reaching $35.56. 265,632 shares of the company’s stock traded hands, compared to its average volume of 353,978. The firm has a market cap of $1,506.49, a PE ratio of 59.62, a P/E/G ratio of 2.26 and a beta of 1.04. Repligen has a 12 month low of $28.48 and a 12 month high of $46.81.

TRADEMARK VIOLATION WARNING: “Repligen Co. (RGEN) Expected to Post Earnings of $0.12 Per Share” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another website, it was copied illegally and republished in violation of United States and international copyright law. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/12/09/repligen-co-rgen-expected-to-post-earnings-of-0-12-per-share.html.

Repligen Company Profile

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Get a free copy of the Zacks research report on Repligen (RGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Repligen (NASDAQ:RGEN)

Receive News & Stock Ratings for Repligen Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Co. and related stocks with our FREE daily email newsletter.